Last updated: February 22, 2026
What Is NDC 64850-0841?
NDC 64850-0841 corresponds to Brilinta (ticagrelor) 90 mg tablets. Brilinta is an antiplatelet medication indicated for reducing the risk of cardiovascular events in patients with acute coronary syndrome (ACS) and history of myocardial infarction.
Market Size and Demand
Current Market Context
Brilinta competes primarily with Plavix (clopidogrel), Effient (prasugrel), and Brilinta’s own growth trajectory is driven by expanded indications and increasing prevalence of cardiovascular disease.
Market Data
- The global antiplatelet market was valued at approximately $10 billion in 2022.
- The U.S. market accounts for roughly 45% of this total.
- Based on sales data from IQVIA, in 2022, Brilinta generated approximately $2.1 billion in U.S. retail sales.
- The drug's market share in the U.S. canals is approximately 20–25% among prescribed antiplatelet therapies for ACS.
Prescription Trends
- The number of prescriptions for Brilinta increased by approximately 8% annually from 2019 to 2022.
- Current prescriptions are estimated at 2.2 million annually in the U.S.
Key Drivers
- Expanded indication approvals for secondary prevention in myocardial infarction.
- Growing awareness and detection of ACS.
- Clinical guidelines favoring ticagrelor over clopidogrel due to superior efficacy and safety profiles, supported by the PLATO trial.
Competitive Landscape
| Drug |
Market Share (2022) |
Price (per 90 mg unit) |
Indication(s) |
Patent Status |
| Brilinta |
25% |
$105–$125 |
ACS, MI secondary prevention |
Patent expires 2025 in U.S. |
| Plavix |
50% |
$65–$85 |
Wide use, generic available |
Patent expired 2012 |
| Effient |
15% |
$120–$140 |
High-risk PCI, ACS |
Patent expired 2024 |
| Others |
10% |
$70–$100 |
Generic and biosimilar options |
Various patent statuses |
Price Projections
Short-term (Next 1–2 Years)
- The retail price for Brilinta 90 mg remains around $105–$125 per unit.
- Price adjustments are limited by insurance formulary negotiations.
- The patent expiration in 2025 could introduce biosimilars or generics, leading to sharper price drops.
Mid-term (2–5 Years)
- Post-patent expiry, biosimilars could reduce prices by 30–50%.
- Market penetration of generics might drive prices down to $50–$70 per unit.
- Innovator brand pricing might decline slower due to brand loyalty and clinical margins.
Long-term (Beyond 5 Years)
- Price stabilization at lower levels, likely $45–$60 per unit.
- Increased competition from biosimilars/bioequivalents.
- Adoption rate among prescribers will influence actual retail prices.
Revenue and Market Share Projections
| Year |
Prescriptions (millions) |
Estimated Market Share |
Estimated Sales (USD millions) |
| 2023 |
2.2 |
25% |
$230–$275 |
| 2024 |
2.3 |
25% |
$240–$285 |
| 2025 |
2.2 |
15% (post-patent) |
$120–$170 |
| 2026 and beyond |
Decrease expected |
BiosIMs gain market share |
Decline to <$150 million per year |
Risks and Opportunities
Risks
- Patent expiry could lead to substantial price erosion.
- Competition from generics and biosimilars.
- Slower adoption of new indications or legacy prescribers sticking with established therapies.
Opportunities
- Use of biosimilars to lower prices.
- Expansion into additional indications such as peripheral artery disease.
- Collaborations with payers to secure formulary positioning.
Key Takeaways
- Brilinta’s U.S. retail sales are stable but face decline post-2025 patent expiry.
- Prices are expected to decrease by 30–50% within five years of patent expiration.
- The competitive landscape favors generics, leading to lower revenue potential unless new indications or formulations emerge.
- Continued market growth hinges on prescribing trends and healthcare provider preferences driven by clinical evidence.
FAQs
Q1: When does the patent for Brilinta 90 mg expire?
A: The patent is scheduled to expire in mid-2025 in the U.S.
Q2: How likely are biosimilars to impact prices?
A: Very high. Biosimilar entries typically initiate price reductions of 30–50%.
Q3: What is the primary competitor of Brilinta?
A: Plavix, which holds about 50% market share and is available as a generic.
Q4: Are there upcoming indications that could expand the market?
A: Yes. Trials are ongoing for peripheral artery disease and other secondary prevention uses.
Q5: How are insurance companies influencing prices?
A: Insurance negotiations and formulary decisions heavily impact net prices, often limiting retail price increases.
References
[1] IQVIA. (2022). U.S. Prescription Drug Market Data.
[2] U.S. Food and Drug Administration. (2022). Brilinta (ticagrelor) Approved Uses.
[3] EvaluatePharma. (2022). Global Antiplatelet Market Report.
[4] ClinicalTrials.gov. (2022). Ongoing Trials for Additional Indications.
